Bcl-xL inhibits Bax, which is in turn required to activate effector Caspases, and it has been shown that the overexpression of Bcl-xL potently blocks axon degeneration following TD (Figure 2A) (Vohra et al., 2010; Simon et al., 2016). The gene discussed is BAX; the disease is thanatophoric dysplasia.